Age-dependent decrease of anti-HBs titers and effect of booster doses using 2 different vaccines in Palestinian children vaccinated in early childhood

References

• Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, Lo KJ, Shih YT. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. Jama 1987; 257:2597-603; PMID:3573257; http://dx.doi.org/10.1001/jama.1987.03390190075023
   PubMed Web of Science ®Google Scholar
• Organization WH. Immunization coverage. 2014: Fact sheet N°378.
   Google Scholar
• Su WJ, Liu CC, Liu DP, Chen SF, Huang JJ, Chan TC, Chang MH. Effect of age on the incidence of acute hepatitis B after 25 years of a universal newborn hepatitis B immunization program in Taiwan. J Infect Dis 2012; 205:757-62; PMID:22262790; http://dx.doi.org/10.1093/infdis/jir852
   PubMed Web of Science ®Google Scholar
• Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27:6550-7; PMID:19729084; http://dx.doi.org/10.1016/j.vaccine.2009.08.048
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, Bulkow L, Fiore AE, Bell BP, Hennessy TW. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390-6; PMID:19785526; http://dx.doi.org/10.1086/606119
   PubMed Web of Science ®Google Scholar
• Mele A, Tosti ME, Mariano A, Pizzuti R, Ferro A, Borrini B, Zotti C, Lopalco P, Curtale F, Balocchini E, et al. Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: areas of improvement and emerging challenges. Clin Infect Dis 2008; 46:868-75; PMID:18269332; http://dx.doi.org/10.1086/528687
   PubMed Web of Science ®Google Scholar
• Ding Y, Sheng Q, Ma L, Dou X. Chronic HBV infection among pregnant women and their infants in Shenyang, China. Virol J 2013; 10:17; PMID:23294983; http://dx.doi.org/10.1186/1743-422X-10-17
   PubMed Web of Science ®Google Scholar
• Chang MH. Breakthrough HBV infection in vaccinated children in Taiwan: surveillance for HBV mutants. Antivir Ther 2010; 15:463-9; PMID:20516566; http://dx.doi.org/10.3851/IMP1555
   PubMed Web of Science ®Google Scholar
• Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-9; PMID:1697396; http://dx.doi.org/10.1016/0140-6736(90)91874-A
   PubMed Web of Science ®Google Scholar
• Gerlich WH. Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation. J Clin Virol 2006; 36(Suppl 1):S18-22; PMID:16831688; http://dx.doi.org/10.1016/S1386-6532(06)80004-1
   PubMedGoogle Scholar
• Gerlich WH. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol 2015; 204:39-55; PMID:25523195; http://dx.doi.org/10.1007/s00430-014-0373-y
   PubMed Web of Science ®Google Scholar
• Coates T, Wilson R, Patrick G, Andre F, Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001; 23:392-403; PMID:11318074; http://dx.doi.org/10.1016/S0149-2918(01)80044-8
   PubMed Web of Science ®Google Scholar
• Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, Gorecki M, Gerlich WH. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 1994; 12:1453-9; PMID:7533967; http://dx.doi.org/10.1016/0264-410X(94)90155-4
   PubMed Web of Science ®Google Scholar
• Shapira MY, Zeira E, Adler R, Shouval D. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 2001; 34:123-7; PMID:11211888; http://dx.doi.org/10.1016/S0168-8278(00)00082-9
   PubMed Web of Science ®Google Scholar
• Yerushalmi B, Raz R, Blondheim O, Shumov E, Koren R, Dagan R. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Pediatr Infect Dis J 1997; 16:587-92; PMID:9194109; http://dx.doi.org/10.1097/00006454-199706000-00009
   PubMed Web of Science ®Google Scholar
• Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rumke H, Boland G, Cerny A, Heim M, Bach D, Schroeder M, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 2006; 24:2781-9; PMID:16455169; http://dx.doi.org/10.1016/j.vaccine.2006.01.007
   PubMed Web of Science ®Google Scholar
• Saed N. HM, Nijim Y, Farah N, Jamalia J, Nuser T, Ismael K, Ghantous R, Amer J, Safadi R. Sci-B-Vac is superior to Engerix-B for preventing HBV vertical transmission. 49th European Association for the Study of the Liver International Liver Congress (EASL 2014). London, 2014.
   Google Scholar
• Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Böcher WO, Lu SN, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005; 23:4158-66; PMID:15964484; http://dx.doi.org/10.1016/j.vaccine.2005.03.017
   PubMed Web of Science ®Google Scholar
• Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams IT, Bell BP. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008; 27:881-5; PMID:18756185; http://dx.doi.org/10.1097/INF.0b013e31817702ba
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, Bulkow L, McMahon BJ. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25:6958-64; PMID:17714836; http://dx.doi.org/10.1016/j.vaccine.2007.06.059
   PubMed Web of Science ®Google Scholar
• Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, Bell BP. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120:e373-81; PMID:17636112; http://dx.doi.org/10.1542/peds.2007-0131
   PubMed Web of Science ®Google Scholar
• Wang LY, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. Vaccine 2007; 25:7160-7; PMID:17707557; http://dx.doi.org/10.1016/j.vaccine.2007.07.022
   PubMed Web of Science ®Google Scholar
• Watson B, West DJ, Chilkatowsky A, Piercy S, Ioli VA. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 2001; 19:3164-8; PMID:11312012; http://dx.doi.org/10.1016/S0264-410X(01)00019-6
   PubMed Web of Science ®Google Scholar
• Saffar MJ, Rezai MS. Long-term antibody response and immunologic memory in children immunized with hepatitis B vaccine at birth. Indian Pediatr 2004; 41:1232-7; PMID:15623904
   PubMedGoogle Scholar
• Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, Cuccia M, Mangione R, Marrone F, Negrone FS, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-84; PMID:16226616; http://dx.doi.org/10.1016/S0140-6736(05)67568-X
   PubMed Web of Science ®Google Scholar
• WHO position paper. World Health Organization. Weekly epidemiological record. No. 40, 2009, 84, 405-420 http://www.who.int/wer/2009/wer8440.pdf
   Google Scholar
• Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, Jacquet JM. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 2011; 18:369-75; PMID:20384962; http://dx.doi.org/10.1111/j.1365-2893.2010.01312.x
   PubMed Web of Science ®Google Scholar
• Pande C, Sarin SK, Patra S, Kumar A, Mishra S, Srivastava S, Bhutia K, Gupta E, Mukhopadhyay CK, Dutta AK, et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. J Viral Hepat 2013; 20:801-10; PMID:24168259
   PubMed Web of Science ®Google Scholar
• Mu SC, Lin YM, Jow GM, Chen BF. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol 2009; 50:264-72; PMID:19070923; http://dx.doi.org/10.1016/j.jhep.2008.09.017
   PubMed Web of Science ®Google Scholar
• Xu L, Wei Y, Chen T, Lu J, Zhu CL, Ni Z, Huang F, Du J, Sun Z, Qu C. Occult HBV infection in anti-HBs-positive young adults after neonatal HB vaccination. Vaccine 2010; 28:5986-92; PMID:20637763; http://dx.doi.org/10.1016/j.vaccine.2010.06.106
   PubMed Web of Science ®Google Scholar
• Feeney SA, McCaughey C, Watt AP, Agnaf MR, McDougall N, Wend UC, Gerlich WH, Coyle PV. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. J Med Virol 2013; 85:597-601; PMID:23359331; http://dx.doi.org/10.1002/jmv.23513
   PubMed Web of Science ®Google Scholar
• Stramer SL, Wend U, Candotti D, Foster GA, Hollinger FB, Dodd RY, Allain JP, Gerlich W. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364:236-47; PMID:21247314; http://dx.doi.org/10.1056/NEJMoa1007644
   PubMed Web of Science ®Google Scholar
• Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine. Med Microbiol Immunol 2015; 204:57-68; PMID:25557605; http://dx.doi.org/10.1007/s00430-014-0374-x
   PubMed Web of Science ®Google Scholar
• Yassin K, Awad R, Tebi AJ, Queder A, Laaser U. Prevalence and risk factors of HBsAg in Gaza: implications for prevention and control. J Infect 2002; 44:252-6; PMID:12099733; http://dx.doi.org/10.1053/jinf.2001.0998
   PubMed Web of Science ®Google Scholar
• Seto D, West DJ, Ioli VA. Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. Pediatr Infect Dis J 2002; 21:793-5; PMID:12233715; http://dx.doi.org/10.1097/00006454-200208000-00021
   PubMed Web of Science ®Google Scholar
• Zinke M, Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J, Soemantri P, Grunert D, Laakmann KH, Gunasekaran R, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin 2009; 5:592-8; PMID:19535920; http://dx.doi.org/10.4161/hv.9051
   PubMed Web of Science ®Google Scholar
• Steiner M, Ramakrishnan G, Gartner B, Van Der Meeren O, Jacquet JM, Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis 2010; 10:9; PMID:20078876; http://dx.doi.org/10.1186/1471-2334-10-9
   PubMed Web of Science ®Google Scholar
• Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 2003; 22:157-63; PMID:12586980
   PubMed Web of Science ®Google Scholar
• Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995; 126:716-21; PMID:7751994; http://dx.doi.org/10.1016/S0022-3476(95)70398-5
   PubMed Web of Science ®Google Scholar
• Hellstrom UB, Madalinski K, Sylvan SP. PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen. Virol J 2009; 6:7; PMID:19154574; http://dx.doi.org/10.1186/1743-422X-6-7
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H, Margolis HS. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333-41; PMID:15738452; http://dx.doi.org/10.7326/0003-4819-142-5-200503010-00008
   PubMed Web of Science ®Google Scholar
• Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. Hepatology 1999; 29:924-7; PMID:10051499; http://dx.doi.org/10.1002/hep.510290327
   PubMed Web of Science ®Google Scholar
• Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, Abdo AA. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect 2008; 57:404-9; PMID:18829116; http://dx.doi.org/10.1016/j.jinf.2008.08.008
   PubMed Web of Science ®Google Scholar
• Carollo M, Palazzo R, Bianco M, Pandolfi E, Chionne P, Fedele G, Tozzi AE, Carsetti R, Roman∫ L, Ausiello CM. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level. Vaccine 2013; 31:506-13; PMID:23174200; http://dx.doi.org/10.1016/j.vaccine.2012.11.029
   PubMed Web of Science ®Google Scholar
• Ogata N, Cote PJ, Zanetti AR, Miller RH, Shapiro M, Gerin J, Purcell RH. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology 1999; 30:779-86; PMID:10462386; http://dx.doi.org/10.1002/hep.510300309
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61:703-11; PMID:25412906; http://dx.doi.org/10.1002/hep.27609
   PubMed Web of Science ®Google Scholar
• Harder T, Remschmidt C, Falkenhorst G, Zimmermann R, Hengel H, Ledig T, Oppermann H, Zeuzem S, Wicker S. Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56:1565-76; PMID:24170086; http://dx.doi.org/10.1007/s00103-013-1845-8
   PubMedGoogle Scholar
• Abdelnabi Z, Saleh N, Baraghithi S, Glebe D, Azzeh M. Subgenotypes and mutations in the s and polymerase genes of hepatitis B virus carriers in the west bank, palestine. PLoS One 2014; 9:e113821; PMID:25503289
   PubMedGoogle Scholar
• Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003; 187:134-8; PMID:12508157; http://dx.doi.org/10.1086/345871
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Theamboonlers A, Hirsch P, Vimolket T, Sinlaparatsamee S, Chaiear K, Siraprapasiri T, Khwanjaipanich S, Owatanapanich S, Chunsuttiwat S. Persistence of antibodies to the surface antigen of the hepatitis B virus (anti-HBs) in children subjected to the Expanded Programme on Immunization (EPI), including hepatitis-B vaccine, in Thailand. Ann Trop Med Parasitol 2000; 94:615-21; PMID:11064763
   PubMed Web of Science ®Google Scholar